Biovica wins Pharma Services work order worth about USD 287,000 from existing customer

• Biovica received a new Pharma Services work order from an existing tier-2 pharmaceutical customer for DiviTum TKa testing.
• Order value about USD 287,000.
• Work supports an early-stage breast cancer program evaluating a novel CDK2/4 inhibitor therapy.
• Testing to run at Biovica’s CLIA-certified lab in San Diego; sample testing expected to start January-February 2027.
• Program targeted for completion in December 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.